Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.50USD
16 Feb 2018
Change (% chg)

$-0.22 (-3.85%)
Prev Close
$5.72
Open
$5.67
Day's High
$5.83
Day's Low
$5.36
Volume
31,846
Avg. Vol
61,638
52-wk High
$14.09
52-wk Low
$4.77

Select another date:

Thu, Nov 9 2017

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

BRIEF-Nabriva Therapeutics announces pricing of public offering of ordinary shares of nearly $80 mln

* Nabriva Therapeutics announces pricing of public offering of ordinary shares of approximately $80 million

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

UPDATE 2-Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Sept 18 Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

Nabriva's pneumonia drug meets main goal in late-stage study

Sept 18 Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading.

BRIEF-Nabriva therapeutics announces positive topline results

* Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia

Select another date: